Latest News

Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma

Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T cell mediated killing of CD20+ cells.

Treatment for Accelerating Postop Bowel Function Gets Fast Track Status

LB1148 is a broad-spectrum serine protease inhibitor designed to neutralize digestive enzymes and potentially reduce intestinal damage.

Efgartigimod SC Formulation Gets Priority Review for Myasthenia Gravis

Efgartigimod is currently marketed under the trade name Vyvgart and is available as a single-dose vial for intravenous infusion after dilution.

FDA: Prolia Use in Dialysis Patients May Cause Severe Hypocalcemia

According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.

Most Phase 3 Trials of Newly Diagnosed Glioblastoma Show No Improvement in OS

Most recent phase 3 trials of patients with newly diagnosed glioblastoma have shown no significant improvement in overall survival with the experimental treatment.

Serdexmethylphenidate Gets Orphan Drug Status for Idiopathic Hypersomnia

Serdexmethylphenidate is a proprietary prodrug of d-methylphenidate.

Sezaby Approved to Treat Seizures in Term and Preterm Infants

The FDA has approved Sezaby (phenobarbital sodium powder for injection) for the treatment of neonatal seizures in term and preterm infants.

FDA Approves Additional Dosing Schedule for Rylaze

The MWF dosing option was approved under the Real-Time Oncology Review program based on data from the intramuscular administration part of a phase 2/3 trial.

Continuing ACE Inhibitors Despite Potassium Change Can Have Benefits

Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.

CDC: Priorix, M-M-R II Fully Interchangeable for MMR Vaccination

Immune responses after Priorix administration were noninferior to those observed with M-M-R II.

AAP Issues Updated Guidance on Palivizumab Use for the 2022-2023 RSV Season

For regions with high levels of RSV disease activity in the fall and winter, the AAP supports the use of more than 5 consecutive doses of palivizumab to eligible infants.

Consolidative Stem Cell Transplant May Improve Outcomes Among Patients With Peripheral T-Cell Lymphoma

Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.

Apixaban Tied to Lower Risk of Gastrointestinal Bleeding

Findings were consistent for patients aged 80 years or older and patients with chronic kidney disease, who are often underrepresented in clinical trials.

Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk, Early Breast Cancer

Dose-dense adjuvant chemotherapy improves disease-free survival in high-risk early breast cancer, according to updated results from the GIM2 trial.

Standing Orders for Primary Prophylaxis Colony-Stimulating Factor to Improve Guideline Adherence

Researchers sought to determine if automated standing orders for prophylaxis colony-stimulating factor would improve adherence to clinical guidelines for use according to risk for febrile neutropenia.

Stigma May Be a Barrier to Lung Cancer Advocacy Among Patients

Results of a cross-sectional survey explain why patients with lung cancer may be reluctant to get involved in advocacy.

Exercise, Physical Activity Beneficial Among Patients With Kidney Cancer

In a study of patients who had ever been diagnosed with kidney cancer, those who reported exercise or physical activity in the past 30 days had reduced likelihood of reporting worse physical and mental health.

Standardized Screening Increases Recognition of Distress in Patients With Cancer

A Plan-Do-Study-Act approach was used to validate a tool for measuring distress and clinical depression in patients with cancer.

High Incidence of Anticoagulation-Associated Abnormal Menstrual Bleeding in Women After Venous Thromboembolism

Researchers sought to determine whether there was a link between abnormal menstrual bleeding and treatment with anticoagulants for VTE.

Zejula Use for Second-Line Maintenance Treatment Restricted

The decision to restrict the indication follows an FDA review of the double-blind, placebo-controlled phase 3 ENGOT-OV16/NOVA trial.